vs
Global Medical REIT Inc.（GMRE）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Global Medical REIT Inc.的1.8倍（$69.8M vs $38.4M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -16.0%，领先400.0%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 9.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 4.6%）
医疗地产信托公司（MPT）是总部位于美国阿拉巴马州伯明翰的国际房地产投资信托基金，主要在美国和欧洲投资收购医疗机构与营利性医疗控股公司。多数收购采用售后回租模式：原业主将物业出售给MPT后转为承租方，租户通常需要签订长期三净租约。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
GMRE vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.8倍
$38.4M
营收增速更快
RIGL
高出12.0%
9.2%
净利率更高
RIGL
高出400.0%
-16.0%
两年增速更快
RIGL
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.4M | $69.8M |
| 净利润 | $-6.1M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | -16.0% | 384.0% |
| 营收同比 | 9.2% | 21.2% |
| 净利润同比 | -309.2% | 1769.2% |
| 每股收益（稀释后） | $-0.48 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMRERIGL
| Q4 25 | $38.4M | $69.8M | ||
| Q3 25 | $37.2M | $69.5M | ||
| Q2 25 | $38.0M | $101.7M | ||
| Q1 25 | $34.6M | $53.3M | ||
| Q4 24 | $35.2M | $57.6M | ||
| Q3 24 | $34.3M | $55.3M | ||
| Q2 24 | $34.2M | $36.8M | ||
| Q1 24 | $35.1M | $29.5M |
净利润GMRERIGL
| Q4 25 | $-6.1M | $268.1M | ||
| Q3 25 | $-5.1M | $27.9M | ||
| Q2 25 | $585.0K | $59.6M | ||
| Q1 25 | $3.7M | $11.4M | ||
| Q4 24 | $2.9M | $14.3M | ||
| Q3 24 | $3.4M | $12.4M | ||
| Q2 24 | $-2.0M | $-1.0M | ||
| Q1 24 | $2.3M | $-8.2M |
毛利率GMRERIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率GMRERIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率GMRERIGL
| Q4 25 | -16.0% | 384.0% | ||
| Q3 25 | -13.6% | 40.2% | ||
| Q2 25 | 1.5% | 58.6% | ||
| Q1 25 | 10.8% | 21.5% | ||
| Q4 24 | 8.4% | 24.9% | ||
| Q3 24 | 9.9% | 22.5% | ||
| Q2 24 | -5.7% | -2.8% | ||
| Q1 24 | 6.6% | -27.9% |
每股收益（稀释后）GMRERIGL
| Q4 25 | $-0.48 | $14.11 | ||
| Q3 25 | $-0.45 | $1.46 | ||
| Q2 25 | $-0.01 | $3.28 | ||
| Q1 25 | $0.03 | $0.63 | ||
| Q4 24 | $-0.04 | $0.82 | ||
| Q3 24 | $0.14 | $0.70 | ||
| Q2 24 | $-0.05 | $-0.06 | ||
| Q1 24 | $0.01 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1M | $155.0M |
| 总债务越低越好 | $1.2M | $52.5M |
| 股东权益账面价值 | $509.8M | $391.5M |
| 总资产 | $1.2B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资GMRERIGL
| Q4 25 | $9.1M | $155.0M | ||
| Q3 25 | $7.1M | $137.1M | ||
| Q2 25 | $6.6M | $108.4M | ||
| Q1 25 | $5.4M | $77.1M | ||
| Q4 24 | $6.8M | $77.3M | ||
| Q3 24 | $5.7M | $61.1M | ||
| Q2 24 | $5.0M | $49.1M | ||
| Q1 24 | $1.3M | $49.5M |
总债务GMRERIGL
| Q4 25 | $1.2M | $52.5M | ||
| Q3 25 | $1.2M | $60.0M | ||
| Q2 25 | $14.2M | $60.0M | ||
| Q1 25 | $14.3M | $60.0M | ||
| Q4 24 | $14.4M | $60.0M | ||
| Q3 24 | $14.5M | $60.0M | ||
| Q2 24 | $14.7M | $60.0M | ||
| Q1 24 | $25.7M | $60.0M |
股东权益GMRERIGL
| Q4 25 | $509.8M | $391.5M | ||
| Q3 25 | $485.3M | $117.6M | ||
| Q2 25 | $503.2M | $81.9M | ||
| Q1 25 | $517.4M | $18.6M | ||
| Q4 24 | $534.1M | $3.3M | ||
| Q3 24 | $542.6M | $-14.6M | ||
| Q2 24 | $556.4M | $-29.9M | ||
| Q1 24 | $575.0M | $-31.7M |
总资产GMRERIGL
| Q4 25 | $1.2B | $513.6M | ||
| Q3 25 | $1.3B | $242.5M | ||
| Q2 25 | $1.3B | $206.7M | ||
| Q1 25 | $1.3B | $176.0M | ||
| Q4 24 | $1.3B | $164.0M | ||
| Q3 24 | $1.2B | $139.4M | ||
| Q2 24 | $1.2B | $128.4M | ||
| Q1 24 | $1.3B | $126.5M |
负债/权益比GMRERIGL
| Q4 25 | 0.00× | 0.13× | ||
| Q3 25 | 0.00× | 0.51× | ||
| Q2 25 | 0.03× | 0.73× | ||
| Q1 25 | 0.03× | 3.23× | ||
| Q4 24 | 0.03× | 18.25× | ||
| Q3 24 | 0.03× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.6M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMRERIGL
| Q4 25 | $73.6M | $22.0M | ||
| Q3 25 | $17.6M | $24.0M | ||
| Q2 25 | $22.1M | $30.5M | ||
| Q1 25 | $12.3M | $-893.0K | ||
| Q4 24 | $70.0M | $14.5M | ||
| Q3 24 | $16.3M | $21.7M | ||
| Q2 24 | $18.9M | $302.0K | ||
| Q1 24 | $14.3M | $-5.0M |
现金转化率GMRERIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | 37.84× | 0.51× | ||
| Q1 25 | 3.28× | -0.08× | ||
| Q4 24 | 23.83× | 1.01× | ||
| Q3 24 | 4.81× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
